Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C - a real-world study.
Simon KA, Flisiak R, Łapiński TW, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska KA, Piekarska A, Tronina O, Madej G, Garlicki A, Łucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski MS, Horban A, Knysz B, Tudrujek M, Halota W. Simon KA, et al. Among authors: lucejko m. Clin Exp Hepatol. 2019 Sep;5(3):215-223. doi: 10.5114/ceh.2019.87634. Epub 2019 Sep 5. Clin Exp Hepatol. 2019. PMID: 31598558 Free PMC article.
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, Jaroszewicz J, Zarębska-Michaluk D, Nazzal K, Bolewska B, Bialkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Rostkowska K, Piekarska A, Tronina O, Madej G, Garlicki A, Lucejko M, Pisula A, Karpińska E, Kryczka W, Wiercińska-Drapało A, Mozer-Lisewska I, Jabłkowski M, Horban A, Knysz B, Tudrujek M, Halota W, Simon K. Flisiak R, et al. Among authors: lucejko m. Aliment Pharmacol Ther. 2016 Nov;44(9):946-956. doi: 10.1111/apt.13790. Epub 2016 Sep 9. Aliment Pharmacol Ther. 2016. PMID: 27611776 Free article. Clinical Trial.
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Flisiak R, Janczewska E, Łucejko M, Karpińska E, Zarębska-Michaluk D, Nazzal K, Bolewska B, Białkowska J, Berak H, Fleischer-Stępniewska K, Tomasiewicz K, Karwowska K, Simon K, Piekarska A, Tronina O, Tuchendler E, Garlicki A. Flisiak R, et al. Among authors: lucejko m. J Viral Hepat. 2018 Nov;25(11):1298-1305. doi: 10.1111/jvh.12945. Epub 2018 Jul 3. J Viral Hepat. 2018. PMID: 29888828
Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
Flisiak R, Łucejko M, Mazur W, Janczewska E, Berak H, Tomasiewicz K, Mozer-Lisewska I, Kozielewicz D, Gietka A, Sikorska K, Wawrzynowicz-Syczewska M, Nowak K, Zarębska-Michaluk D, Musialik J, Simon K, Garlicki A, Pleśniak R, Baka-Ćwierz B, Olszok I, Augustyniak K, Stolarz W, Białkowska J, Badurek A, Piekarska A. Flisiak R, et al. Among authors: lucejko m. Adv Med Sci. 2017 Sep;62(2):387-392. doi: 10.1016/j.advms.2017.04.004. Epub 2017 May 26. Adv Med Sci. 2017. PMID: 28554119
siRNA drug development against hepatitis B virus infection.
Flisiak R, Jaroszewicz J, Łucejko M. Flisiak R, et al. Among authors: lucejko m. Expert Opin Biol Ther. 2018 Jun;18(6):609-617. doi: 10.1080/14712598.2018.1472231. Epub 2018 May 8. Expert Opin Biol Ther. 2018. PMID: 29718723 Review.
13 results